Portal de Periódicos da CAPES

SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

2021; Elsevier BV; Volume: 172; Linguagem: Inglês

10.1016/j.addr.2021.01.014

1872-8294

Saborni Chakraborty, Vamsee Mallajosyula, Cristina M. Tato, Gene S. Tan, Taia T. Wang,

Vaccine Coverage and Hesitancy

The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.